公开(公告)号：EP2958562A1

公开(公告)日：2015-12-30

申请号：EP14754282.3

申请日：2014-02-20

申请人： Merck Sharp & Dohme Corp.

发明人： BROCKUNIER, Linda L. ,  CHEN, Helen ,  CHOBANIAN, Harry R. ,  CLEMENTS, Matthew J. ,  CRESPO, Alejandro ,  DEMONG, Duane E. ,  GUO, Yan ,  HAGMANN, William K. ,  MARCANTONIO, Karen M. ,  MILLER, Michael ,  PIO, Barbara ,  PLUMMER, Christopher W. ,  XIAO, Dong

IPC分类号： A61K31/357

CPC分类号： C07D493/04 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D201/00 ,  C07D311/04 ,  C07D311/28 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  C07D491/052

摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.